Claims
- 1. A compound of formula (I): ##STR41## in which: R.sup.1 and R.sup.2 are independently selected from the group consisting of hydrogen atoms, C.sub.1 -C.sub.4 alkyl groups, C.sub.6 -C.sub.10 carbocyclic aryl groups and substituted C.sub.6 -C.sub.10 carbocyclic aryl groups having one to three substituents selected from the group consisting of substituents (a);
- n is 1 or 2;
- A.sup.2 represents a group of formula --Z--Y in which Y represents 1-imidazolyl or 2-, 3- or 4-pyridyl and Z represents a methylene, ethylene, trimethylene or vinylene group or a methylene, ethylene, trimethylene or vinylene group having one or two substituent selected from the group consisting of substituents (b);
- A' represents a group of formula --W--COOH, where W represents a direct bond, a methylene group, an ethylene group, a vinylene group or a substituted methylene, ethylene or vinylene group having one to three substituents selected from the group consisting of substituents (c);
- A.sup.2 is at the 5- or 6-position on the thianaphthene system;
- each broken line represents a single or double carbon-carbon bond between the 4 and 5 or the 6 and 7 positions, provided that, when A.sup.2 is at the 5-position, there is a single bond between the 6 and 7 positions, and that, when A.sup.2 is at the 6-position, there is a single bond between the 4 and 5 positions;
- substituents (a): C.sub.1 -C.sub.4 alkyl groups, C.sub.1 -C.sub.4 alkoxy groups, C.sub.2 -C.sub.6 alkanoyloxy groups, aromatic carboxylic acyloxy groups, C.sub.2 -C.sub.5 aliphatic carboxylic acylamino groups, aromatic carboxylic acylamino groups, trifluoromethyl groups, halogen atoms, nitro groups, cyano groups, amino groups, C.sub.1 -C.sub.4 alkylamino groups, dialkylamino groups in which each alkyl part is C.sub.1 -C.sub.4, carboxy groups and esters and amides of said carboxy groups, the aromatic parts of said aromatic acyloxy and aromatic acylamino groups being C.sub.6 -C.sub.10 carbocyclic aryl groups which are unsubstituted or have at least one substituent selected from the group consisting of C.sub.1 -C.sub.4 alkyl groups, C.sub.1 -C.sub.4 alkoxy groups and halogen atoms;
- substituents (b): C.sub.1 -C.sub.5 alkyl groups, C.sub.3 -C.sub.6 cycloalkyl groups, C.sub.6 -C.sub.10 carbocyclic aryl groups, and substituted C.sub.8 -C.sub.10 carbocyclic aryl groups having one to three substituents selected from the group consisting of C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, and halogen; and
- substituent (c): C.sub.1 -C.sub.4 alkyl groups, C.sub.6 -C.sub.10 carbocyclic aryl groups and substituted C.sub.6 -C.sub.10 carbocyclic aryl groups having one to three substituents selected from the group consisting of C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy and halogen;
- or a pharmaceutically acceptable salt, ester or amide wherein said esters is C.sub.1 -C.sub.8 alkyl, benzyl, p-nitrobenzyl, benzhydryl, (C.sub.1 -C.sub.4) alkoxycarbonyl-(C.sub.1 -C.sub.4) alkyl, (C.sub.1 -C.sub.4) alkoxycarbonyloxy-(C.sub.1 -C.sub.4) alkyl, phthalidyl, phenacyl, p-nitrophenacyl or (5-methyl-2-oxo-1,3-dioxolen-4-yl) methyl ester; and said amide is a (C.sub.1 -C.sub.4) alkyl amide or di-(C.sub.1 -C.sub.4) alkyl amide thereof.
- 2. A compound as claimed in claim 1, having the formula (I.sup.v): ##STR42## wherein R.sup.1, R.sup.2, W, Y, Z, n and the broken lines are as defined in claim 1.
- 3. A compound as claimed in claim 1 having the formula (I.sup.vi): ##STR43## in which: Y is as defined in claim 1;
- the dotted line represents a double or single bond between the 6- and 7- positions;
- R.sup.1 and R.sup.2 are independently selected from the group consisting of hydrogen atoms and C.sub.1 -C.sub.4 alkyl groups;
- Z represents a methylene, ethylene, trimethylene or vinylene group or a methylene, ethylene, trimethylene or vinylene group having at least one substituent selected from the group consisting of substituents (b');
- W represents a direct bond or a methylene, ethylene or vinylene group; and
- substituents (b')
- C.sub.1 -C.sub.4 alkyl groups, cyclohexyl groups, phenyl groups and substituted phenyl groups having one to three substituents selected from the group consisting of C.sub.1 -C.sub.4 alkyl groups, C.sub.1 -C.sub.4 alkoxy groups and halogen atoms.
- 4. A compound as claimed in claim 3, in which:
- Y and the dotted lines are as defined in claim 9;
- R.sup.1 and R.sup.2 are independently selected from the group consisting of hydrogen atoms, methyl groups and ethyl groups;
- Z represents a methylene group; and W represents a direct bond.
- 5. A compound as claimed in claim 1 having the formula (I.sup.vii): ##STR44## in which: Y is as defined in claim 1;
- the dotted line represents a double or single bond between the 4- and 5- positions;
- R.sup.1 and R.sup.2 are independently selected from the group consisting of hydrogen atoms and C.sub.1 -C.sub.4 alkyl groups;
- Z represents a methylene, ethylene, trimethylene or vinylene group of a methylene, ethylene, trimethylene or vinylene group having at least one substituent selected from the group consisting of substituents (b');
- W represents a direct bond or a methylene, ethylene or vinylene group; and
- substituents (b')
- C.sub.1 -C.sub.4 alkyl groups, cyclohexyl groups, phenyl groups and substituted phenyl groups having one to three substituents selected from the group consisting of C.sub.1 -C.sub.4 alkyl groups, C.sub.1 -C.sub.4 alkoxy groups and halogen atoms.
- 6. A compound as claimed in claim 5, in which:
- Y and the doted line are as defined in claim 11;
- R.sup.1 and R.sup.2 are independently selected from the group consisting of hydrogen atoms, methyl groups and ethyl groups;
- Z represents a methylene group; and
- W represents a direct bond.
- 7. A compound as claimed in claim 1, wherein is selected from the group consisting of 4,5,6,7-tetrahydro-5-(1-imidazolyl)methylthianaphthene-2-carboxylic acid and pharmaceutically acceptable salts, esters and amides thereof.
- 8. A pharmaceutical composition comprising an effective amount to inhibit TXA.sub.2 biosynthesis of the compound of claim 1 or its pharmaceutically acceptable salt, ester or amide, in a pharmaceutically acceptable carrier.
- 9. A composition as claimed in claim 8, wherein said compound has the formula (I.sup.vi): ##STR45## in which: the dotted line represents a double or single bond between the 6- and 7- positions;
- R.sup.1 and R.sup.2 are independently selected from the group consisting of hydrogen atoms and C.sub.1 -C.sub.4 alkyl groups;
- Z represents a methylene, ethylene, trimethylene or vinylene group or a methylene, ethylene, trimethylene or vinylene group having at least one substituent selected from the group consisting of substituents (b');
- W represents a direct bond or a methylene, ethylene or vinylene group; and
- substituents (b ')
- C.sub.1 -C.sub.4 alkyl groups, cyclohexyl groups, phenyl groups and substituted phenyl groups having one to three substituents selected from the group consisting of C.sub.1 -C.sub.4 alkyl groups, C.sub.1 -C.sub.4 alkoxy groups and halogen atoms.
- 10. A composition as claimed in claim 9, in which:
- R.sup.1 and R.sup.2 are independently selected from the group consisting of hydrogen atoms, methyl groups and ethyl groups;
- Z represents a methylene group; and
- W represents a direct bond.
- 11. A composition as claimed in claim 8, wherein said compound has the formula (I.sup.vii): ##STR46## in which: the dotted line represents a double or single bond between the 4- and 5- positions;
- R.sup.1 and R.sup.2 are independently selected from the group consisting of hydrogen atoms and C.sub.1 -C.sub.4 alkyl groups;
- Z represents a methylene, ethylene, trimethylene or vinylene group or a methylene, ethylene, trimethylene or vinylene group having at least one substituent selected from the group consisting of substituents (b');
- W represents a direct bond or a methylene, ethylene or vinylene group; and
- substituents (b')
- C.sub.1 -C.sub.4 alkyl groups, cyclohexyl groups, phenyl groups and substituted phenyl groups having one to three substituents selected from the group consisting of C.sub.1 -C.sub.4 alkyl groups, C.sub.1 -C.sub.4 alkoxy groups and halogen atoms.
- 12. A composition as claimed in claim 11, in which:
- the dotted line are as defined in claim 11;
- R.sup.1 and R.sup.2 are independently selected from the group consisting of hydrogen atoms, methyl groups and ethyl groups;
- Z represents a methylene group; and
- W represents a direct bond.
- 13. A pharmaceutical composition comprising an effective amount to inhibit TXA.sub.2 biosynthesis of the compound of claim 2 or its pharmaceutically acceptable salt, ester or amide, in a pharmaceutically acceptable carrier.
- 14. A composition as claimed in claim 8, in which said compound is selected from the group consisting of:
- 4. 5,6,7-tetrahydro-5-(1-imidazolyl)methylthianaphthene-2-carboxylic acid; or
- a pharmaceutically acceptable salt, ester or amide thereof.
- 15. A method for treatment or prophylaxis of thrombosis which comprises administering an effective amount of the compound of claim 1 or its pharmaceutically acceptable salt, ester or amide.
- 16. A method as claimed in claim 15, in which said compound is selected from the group consisting of:
- 4. 5,6,7-tetrahydro-5-(1-imidazolyl)methylthianaphthene-2-carboxylic acid; or
- a pharmaceutically acceptable salt, ester or amide thereof.
Priority Claims (2)
Number |
Date |
Country |
Kind |
61-16501 |
Jan 1986 |
JPX |
|
1-228769 |
Sep 1986 |
JPX |
|
Parent Case Info
This is a division of application Ser. No. 07/007,375 filed Jan. 27, 1987 which has issued as U.S. Pat. No. 4,847,272 on July 11, 1989.
US Referenced Citations (3)
Non-Patent Literature Citations (1)
Entry |
Terada et al., CA 108:376637n. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
7375 |
Jan 1987 |
|